Dhansa Labs revenue rises 10.82%, plans Rs 30 crore expansion

1 min read     Updated on 12 Jun 2026, 04:35 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Dhansa Labs reported a 10.82% increase in revenue to ₹14,153.72 lakhs and a 15.47% rise in PAT to ₹552.26 lakhs for FY26. The company announced a ₹30 crore investment to expand Atrazine manufacturing capacity, targeting ₹120-140 crores in additional revenue. Additionally, subsidiaries are developing a ₹120 crore CBG project and a biomass pellet venture, with the CBG plant set to commence operations by July 2027.

powered bylight_fuzz_icon
42001936

*this image is generated using AI for illustrative purposes only.

Dhansa Labs Limited reported a 10.82% year-on-year increase in revenue from operations to ₹14,153.72 lakhs for the financial year ended March 31, 2026. Profit after tax (PAT) grew by 15.47% to ₹552.26 lakhs, while EBITDA stood at ₹1,221.80 lakhs, a growth of 6.31%. The company maintained an EBITDA margin of 8.55% and a PAT margin of 3.87% during the period.

Management outlined a significant capacity expansion initiative in its core agrochemical business, including a planned addition of Atrazine manufacturing capacity. This project involves an estimated investment of approximately ₹30 crores and is expected to commence operations by August 2026. Upon stabilization, the company anticipates the project will generate additional annual revenues of ₹120 crores to ₹140 crores, with an initial target of ₹40 crores in the current year.

Diversification and Subsidiaries

The company is diversifying through its subsidiaries, Dhansa Green Energy Private Limited and Dhansa Biofuels Power Private Limited. Dhansa Green Energy is developing a 15 TPD Compressed Biogas (CBG) project in the Bundi district of Rajasthan with an estimated cost exceeding ₹120 crores. Commercial operations are expected to commence by July 2027. The project includes a lease for 350 acres to cultivate Napier grass, ensuring a sustainable feedstock ecosystem and supporting carbon credit generation.

Dhansa Biofuels Power Private Limited is focusing on biomass pellets. The total planned investment for the BioFuel segment is approximately ₹120 crores. Management stated that financial closure for the CBG project is secured, with ₹85 crores in debt finalized and the remaining funding sourced from warrants issued in August 2025.

Financial Guidance and Metrics

For the upcoming financial year, the company expects revenue growth of approximately 20%. Current capacity utilization stands at 71%. Management addressed concerns regarding working capital utilization, noting that funds raised via IPO were used to reduce creditors, increase debtors, and improve stock levels to mitigate material scarcity issues.

Metric FY26 Value YoY Growth
Revenue from Operations ₹14,153.72 lakhs 10.82%
EBITDA ₹1,221.80 lakhs 6.31%
PAT ₹552.26 lakhs 15.47%
EBITDA Margin 8.55% -
PAT Margin 3.87% -

Historical Stock Returns for Dhansa Labs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.78%-13.72%-20.73%-47.72%-50.06%-78.15%

How will the company fund the remaining gap for the BioFuel segment given that financial closure is secured only for the CBG project?

What are the expected margins for the new Atrazine capacity compared to the current 8.55% EBITDA margin?

How does the company plan to bridge the gap between current 71% capacity utilization and the 20% revenue growth target for the upcoming year?

Dhansa Labs FY26 PAT rises 15.47% to ₹552.26 lakh

2 min read     Updated on 06 Jun 2026, 04:42 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Dhansa Labs Limited reported a 15.47% increase in Profit After Tax (PAT) to ₹552.26 lakh for FY26, with revenue from operations rising 7.82% to ₹14,153.72 lakh. EBITDA grew 6.31% to ₹1,221.80 lakh. The company allotted convertible equity warrants worth ₹4,999.99 lakh and is expanding capacity through Atrazine manufacturing and renewable energy projects via its subsidiaries.

powered bylight_fuzz_icon
41374382

*this image is generated using AI for illustrative purposes only.

Dhansa Labs Limited reported a 15.47% increase in Profit After Tax (PAT) to ₹552.26 lakh for the financial year ended March 31, 2026, compared to ₹478.27 lakh in the previous year. Revenue from operations rose 7.82% to ₹14,153.72 lakh from ₹13,126.99 lakh in FY25. The company’s EBITDA stood at ₹1,221.80 lakh, reflecting a growth of 6.31%, with an EBITDA margin of 8.55% and a PAT margin of 3.87%.

Financial Performance

The Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026. For the quarter ended March 31, 2026, net profit was ₹208.94 lakh, while revenue from operations was ₹4,053.73 lakh. Total income for the year increased to ₹14,284.68 lakh from ₹13,318.60 lakh in the prior year. The finance cost for the six months ended March 31, 2026, was reduced by ₹58.94 lakh due to the reversal of costs previously recognized that should have been capitalised.

Capital Allocation and Warrants

During FY26, the company allotted 1,08,69,565 convertible equity warrants on a preferential basis at an issue price of ₹46 per warrant, aggregating to ₹4,999.99 lakh. The company received ₹1,697.50 lakh towards warrant subscription as of March 31, 2026. These funds were fully utilized for general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure, and land-related advances. There was no deviation in the utilization of funds raised.

Strategic Initiatives and Subsidiaries

The company is undertaking a significant capacity expansion initiative aimed at strengthening its manufacturing capabilities, including the planned introduction of Atrazine manufacturing. This project has the potential to contribute approximately ₹120–140 crore in additional annual revenue. Dhansa Labs is also diversifying through its subsidiaries, Dhansa Green Energy Private Limited and Dhansa Biofuels Power Private Limited. Dhansa Green Energy is progressing towards the commissioning of a Compressed Biogas (CBG) project with a capacity of 15 tonnes per day and is developing a Napier Grass project in the Bundi district of Rajasthan. Dhansa Biofuels Power is focused on developing biomass pellets as an alternative to coal.

Auditor’s Report and Compliance

Statutory auditors M/s Kapish Jain & Associates issued an audit report with an unmodified opinion on the audited financial results. The company assessed the impact of the New Labour Codes, effective from November 21, 2025, and recognized an incremental liability of ₹9.46 lakh pertaining to gratuity and leave encashment within employee benefit expenses. The consolidated financial results include the performance of its subsidiaries.

Metric FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from operations 14,153.72 13,126.99
Total income 14,284.68 13,318.60
Total expenses 13,545.05 12,714.77
Net profit 552.26 478.27
Basic EPS (₹) 2.30 2.06

Historical Stock Returns for Dhansa Labs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.78%-13.72%-20.73%-47.72%-50.06%-78.15%

What is the expected timeline for the commissioning of the Atrazine manufacturing facility and the Compressed Biogas project?

How will the conversion of the preferential warrants impact earnings per share once the equity is issued?

What are the projected revenue contributions from the biomass pellets and Napier Grass projects in the next fiscal year?

More News on Ambey Laboratories

1 Year Returns:-50.06%